Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& \) b* H, c/ r, ~# y7 L
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
% ?! y; {6 U+ U. t, Y) d+ Author Affiliations
- s# c- l" U) V6 _
6 M) [# x# L: W' g# w% {4 k1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
! s- t: i3 W8 ]; z/ [2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' g7 s0 \) [4 r4 n( x, ~, m3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ [) g- R: Y6 }" ?. i8 q4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) m0 [6 g) e3 V
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ' W+ S2 I2 k p% y+ j; M6 A
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
& U3 O% t& R+ }( ]* d, ^7Kinki University School of Medicine, Osaka 589-8511, Japan
* p* r: X3 m( c7 ?! S/ m8Izumi Municipal Hospital, Osaka 594-0071, Japan * N' c$ E, B0 ~+ e5 ?8 {+ h0 N
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 4 u" c/ _& L) x6 G' ~. I
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
6 |6 `7 u" L/ z8 K6 H* C& qAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
; H& ^; O; k( {+ `* [1 Q m- ~, P$ F$ Y" q& f- v
|